As a senior expert in antibody development, Creative Biolabs owns lots of scientists who are proficient in non-IgG therapeutic antibody production, engineering, and application. Our professional scientists are pleased to provide the custom non-IgG antibody isotype switching service against diverse disease biomarkers to diagnose and treat related diseases efficiently. We believe our first-class services will fit your needs in your most critical research requirements.
For many indication therapies, choosing the appropriate antibody isotype and format is as critical as having the right antigen specificity. Creative Biolabs can help you obtain a suitable isotype based on your parental antibody and intended application. Utilizing our advanced antibody engineering techniques and expertise, our scientists are able to switch antibody isotypes among these five isotypes (IgG, IgA, IgD, IgE, and IgM) of any species.
Our Service
Antibody isotype switching service is a specialized solution designed to assist researchers in converting an antibody from one immunoglobulin isotype (e.g., IgM) to another (e.g., IgG, IgA, or IgE). This service is crucial for optimizing antibody functionality, enhancing specificity, and studying the role of antibodies in immune responses.
Service Process
1. Customer Requirement Assessment
- Collect information on the target antibody sequence (e.g., heavy and light chain sequences).
- Confirm the desired isotype (e.g., switching from IgM to IgG1, IgA, IgE, etc.) and specific application requirements.
- Develop a customized project plan and provide a timeline.
2. Antibody Gene Design and Synthesis
- Redesign the heavy chain gene by replacing the constant region (CH) to achieve the desired isotype.
- Use optimized gene synthesis techniques to ensure accurate sequence construction and efficient expression.
3. Cell Line Construction and Transfection
- Transfect the redesigned heavy chain gene into an optimized expression system (e.g., HEK 293 or CHO cells).
- Optimize cell culture conditions to enhance antibody secretion and proper folding.
4. Antibody Expression and Purification
- Collect culture supernatants and purify the target antibody using protein A/G columns or isotype-specific affinity purification.
- Concentrate and perform buffer exchange to meet quality standards for downstream applications.
5. Antibody Characterization and Validation
- Analyze antibody purity and integrity using SDS-PAGE, electrophoresis, and HPLC.
- Evaluate antibody specificity and affinity through ELISA, BLI, or SPR methods.
- Validate functional properties, such as complement activation or Fc receptor binding.
6. Reporting and Delivery
- Provide a comprehensive experimental report, including antibody sequence details, purification data, and validation results.
- Deliver purified antibody samples and detailed experimental records according to customer requirements.
Optional Services:
- Customized optimization of antibody functionality (e.g., glycosylation analysis).
- Small-scale pilot production or large-scale antibody preparation.
Highlights
-
Precise Isotype Conversion
Achieve accurate antibody isotype switching by targeting the immunoglobulin heavy chain constant region, ensuring seamless conversion to the desired isotype. -
Customizable Solutions for Specific Needs
Tailor-made antibody isotype options, such as IgA, IgM, or IgE, to meet diverse research and application requirements. -
Enhanced Antibody Functionality
Improve antibody properties like stability, effector functions, and compatibility with Fc-mediated mechanisms such as ADCC and CDC. -
High Purity and Yield
Advanced purification techniques ensure high-quality, purified antibody products suitable for critical downstream applications. -
Broad Range of Applications
Supports various fields, including vaccine development, immunotherapy research, and basic studies in immune mechanisms. -
Optimized Expression Systems
Utilize HEK 293 or CHO cells with optimized culture conditions for efficient antibody expression and correct folding. -
Time and Cost Efficiency
Streamlined processes reduce research timelines and deliver ready-to-use antibodies, saving time and resources for researchers. -
Integrated Reporting and Support
Detailed experimental reports with antibody sequence, validation data, and performance metrics, providing full transparency and support.
Background
In the human body, immunoglobulin class switching takes place rapidly after the activation of mature naive B cells, leading to a switch from the expression of IgM and IgD to the expression of IgG, IgE, or IgA. The first class of immunoglobulin produced in an immune response is IgM. With the immune response progressing, the immunoglobulins produced by B cells change from predominantly IgM to IgG, IgE, or IgA classes depending upon the type of stimulation. In fact, only the constant region of the antibody's heavy chain is altered while the variable region of the heavy chain remains invariable during this process, which results in changes in antibody binding to different effector molecules rather than changes in antigen specificity. This switch can promote the ability of antibodies to remove the pathogen by inducing the immune response that they are expert in.
In vitro, class switching occurs by the deletional recombination between two switch regions, each of which is associated with an H chain constant region gene. During the class-switch recombination (CSR), the constant region of the antibody heavy chain is changed, but the variable region of the heavy chain remains the same. Similarly, this recombinant switching does not change antigen specificity since the variable region does not alter. CSR is initiated by activation-induced cytidine deaminase, which converts cytosines in switching regions to uracils. The uracils are subsequently removed by two DNA-repair pathways, resulting in mutations, single-strand DNA breaks, and the double-strand breaks required for CSR.
Fig. 1 Outline of loop extrusion and class switch recombination center (CSRC) model.1
FAQs
Q1: What information must be provided to initiate the service?
A: Clients need to submit the antibody's heavy and light chain sequences, the desired isotype, and any specific application details to ensure the project is customized appropriately.
Q2: How does the service ensure high-purity antibody production?
A: High-purity antibodies are produced through affinity chromatography (e.g., Protein A/G) and validated using techniques like SDS-PAGE and HPLC.
Q3: What methods are used to validate the functional properties of the antibodies?
A: Validation includes ELISA, BLI, SPR, and Fc receptor binding assays to confirm specificity, affinity, and functional efficacy.
Q4: Can antibody glycosylation be optimized through this service?
A: Yes, glycosylation analysis and optimization are available as optional services to enhance antibody performance for specific applications.
Q5: Which research areas benefit most from this service?
A: The service is applicable to immunotherapy research, vaccine development, antibody functional studies, and exploring immune mechanisms.
Q6: What deliverables are included in the service?
A: Clients receive purified antibody samples, comprehensive experimental reports, validation data, and optional custom analyses, depending on the project requirements.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody - Creative Biolabs
Switching an antibody to a suitable isotype can help it gain better performance in effector functions and disease therapies. As a senior company in antibody research and service providing, Creative Biolabs has bent itself into non-IgG antibody exploration for several years to improve the abilities of our comprehensive antibody services. We can customize our isotype switching services according to your needs and purpose using our extensive antibody engineering technologies and expertise. What you need to do is just directly contact us.
Quotation and Ordering
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Reference
- Dauba, Audrey, and Ahmed Amine Khamlichi. "Long-range control of class switch recombination by transcriptional regulatory elements." Frontiers in Immunology 12 (2021): 738216. Distributed under the Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
